Keyword: Shire

Emerging markets have been holding Takeda back, despite double-digit growth in China. Now, the company could reap some cash by selling some of those products.

Pharma is too preoccupied with short-term growth, so it's going the easier me-too route rather than focusing on "transformative" therapies, the CEO said.

FiercePharma’s most-read headlines of 2018 include industry themes that dominated the year's news or return time and again—and, of course, scandals.

Shire has struck a deal to sell a small biologics manufacturing site in Massachusetts to German CDMO Rentschler.

Takeda is set to gulp up Shire whether disgruntled investors like the deal or not, but its new FDA OK may make it easier to swallow.

The most expensive drugs in the U.S. feature commercial hits as well as lesser-known ones, with several Big Pharma products in the mix.

The Takeda-Shire deal passes investors; Sun suffers from a long list of allegations; J&J and Legend update CAR-T data.

The deal will make Takeda "a more competitive, agile, highly profitable, and therefore more resilient company," said CEO Christophe Weber.

With a critical shareholder vote looming, Takeda's CFO says the company will consider selling up to $10 billion in assets to help fund its Shire buy.

A Chinese researcher claims is the world's first gene-edited babies; Takeda's Shire deal faces last-minute drama; Celltrion wins first Rituxan biosim nod.